Frontline immunotherapy for NSCLC — the tale of the tail
Authors:
- 6 January 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 17 (2) , 73-74
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2019
- OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2019
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2019
- Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivorsCancer Immunology, Immunotherapy, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2018
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016